🔎 Trials Near Me

Hem › Övervikt › Alabama

Kliniska studier för Övervikt i Alabama

31 studier för Övervikt söker deltagare vid platser i Alabama.

Städer i Alabama

Officiell studietext (engelska)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Cahaba Research - Pelham /ID# 282381, Pelham
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT07752979

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • Univ of Alabama Birmingham, Birmingham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07533175

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  • AMR Clinical - Mobile, Mobile
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • University of Alabama - Birmingham, Birmingham
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 28 sep. 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Pinnacle Research Group LLC, Anniston
  • Univ of Alabama Birmingham, Birmingham
  • Chambliss Clinical Trials LLC, Montgomery
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07720271

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Pinnacle Research Group, LLC, Anniston
  • Central Research Associates, Birmingham
  • Cahaba Research - Pelham, Pelham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT07794579

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Digestive Health Specialists, Dothan
RekryterarFas 3
Ålder 18 till 70 · Alla kön · Uppdaterad 24 sep. 2026 · NCT06937099

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Digestive Health Specialists, Dothan
RekryterarFas 3
Ålder 18 till 70 · Alla kön · Uppdaterad 24 sep. 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Birmingham Clinical Research, Birmingham
  • Cullman Clinical Trials, Cullman
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Birmingham Clinical Research, Birmingham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Fairhope
  • Research Site, Huntsville
  • Research Site, Mobile
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07784270

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Cullman Clinical Trials, Cullman
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Alliance For Multispecialty Research - Daphne, Daphne
  • Eastern Shore Research Institute, Fairhope
  • Heart Center Research LLC, Huntsville
  • och 2 fler
RekryterarFas 3
Ålder 45 till 99 · Alla kön · Uppdaterad 22 sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • MFA Clinical Research, Tuscaloosa
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • AMR Clinical, Mobile
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07353931

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Birmingham
  • AURORA-1 Clinical Site, Huntsville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Birmingham
  • AURORA-2 Clinical Site, Huntsville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Lakeview Clinical Research, Guntersville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT07351058

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Pinnacle Research Group, Anniston
  • Alabama Clinical Therapeutics, Birmingham
  • University of Alabama at Birmingham, Birmingham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Birmingham
RekryterarFas 3Friska volontärer välkomna
Ålder 18 till 79 · Alla kön · Uppdaterad 11 sep. 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • Uni of Alabama at Birmingham, Birmingham
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT07770841

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Cullman
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 3 sep. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Pinnacle Research Group LLC, Anniston
  • Alliance For Multispecialty Research - Daphne, Daphne
  • Alliance for Multispecialty Research Mobile, Mobile
RekryterarFas 3
Ålder 18 till 99 · Alla kön · Uppdaterad 3 sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Anniston
  • Kailera Clinical Site, Birmingham
  • Kailera Clinical Site, Cullman
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 3 sep. 2026 · NCT07284875

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Dothan
  • Research Site, Huntsville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 aug. 2026 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Birmingham
  • ACCOMPLISH-1 Research Site, Birmingham
RekryterarFas 3
Ålder 18 till 79 · Alla kön · Uppdaterad 10 aug. 2026 · NCT07654361

Time-restricted Eating for Postpartum Weight Loss

  • University of Alabama at Birmingham, Birmingham
Rekryterar
Ålder 18 och äldre · Kvinnor · Uppdaterad 29 juni 2026 · NCT06491537

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

  • University of Alabama at Birmingham, Birmingham
Rekryterar
Ålder 18 till 45 · Kvinnor · Uppdaterad 24 juni 2026 · NCT05124808

FELLAShip to Better Health

  • The Worship Center Cristian Church, Birmingham
Rekryterar
Ålder 18 och äldre · Män · Uppdaterad 22 jan. 2026 · NCT07220213

Från ClinicalTrials.gov, data hämtad 3 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.